R.S. Analytics
- Sarepta Therapeutics Setting Up For Another Move Upward
- VirnetX And Google? Will Apple Settle, Or Risk Going The Distance?
- 4 Biotech Stocks With Important Catalysts Approaching
- DEFCON 1: 5 Internet Security Stocks To Consider As Cyber Attacks Escalate
- VirnetX: The Fuse Has Been Lit
- Dynavax Shares Poised To Run Higher As Heplisav Approaches Important Catalysts
-
As VirnetX Vs. Apple Patent Trial Draws Near, Be Prepared For The Unusual
- 4 Undervalued Cash-Heavy Stocks With Room To Run Higher
- Heroes And Zeros: PDL Biopharma And Alcatel-Lucent
- Positive Momentum Building For Netflix - 5 Reasons It Is Likely To Continue
-
Will Legal Showdown With VirnetX Cause Apple's CEO To Regret His Words?
- Amarin - A Likely Buyout Candidate For 2012 - Focusing On The Bigger Picture
- 3 Undervalued High-Growth Dividend Stocks Rated Strong Buy And Near 52-Week Lows
- Saddling Up The One-Trick Biotech Pony And Getting Bucked Off: The Questcor Example
- 3 Sub $10 Heavily Shorted High Volume Small Cap Biotechs Rated Buy With Momentum
- 3 Biotechs With Increased Short Interest And Imminent Catalysts Coming Soon
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out
-
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
- Are The Winds Of Settlement Blowing Towards Apple And VirnetX?
- Sarepta Therapeutics - Pressure Mounting For Accelerated FDA Approval For Eteplirsen
- 3 Biotech Companies: 2 To Buy And 1 To Day Trade
- Avanir Pharmaceuticals: Nuedexta's First Birthday - Wiping Away The Tears